Kadmon Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kadmon Holdings, Inc.
While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.
Public Company Edition: Only nine drug developers went public in the US, raising $807m in the first quarter, versus 32 IPOs raising $5.2bn in Q1 of last year. Also, MoonLake closed its SPAC merger, Sanofi priced €650m in sustainability-linked bonds in €1.5bn note sale, and Kaleido will cease operations.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies.
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Kadmon Corporation, LLC
- Romeck Pharma, LLC
- Three Rivers Pharmaceuticals, LLC